Reports Q3 revenue $400k vs $5.4M last year. Mori Arkin, Executive Chairman of Sol-Gel, stated: “Sol-Gel continued to make steady progress in the third quarter as we advance our late-stage pipeline in dermatologic rare diseases. Our pivotal Phase 3 trial of SGT-610 for Gorlin syndrome is ongoing, and we remain focused on executing this study to deliver top-line results in the fourth quarter of 2026. We are particularly excited about the opportunity of at least doubling the potential of this important drug by adding the unmet need of high-frequency BCC.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLGL:
- Sol-Gel Technologies Announces Key Leadership and Auditor Appointments
- Promising Growth and Strategic Financial Moves Make Sol-Gel Technologies a Strong Buy
- Sol-Gel Technologies target adjusted to $50 from $6 at H.C. Wainwright
- Sol Gel Technologies trading resumes
- Sol Gel Technologies trading halted, volatility trading pause